Bristol-Myers Squibb Company (BMY) EV/Sales Ratio: 3.12x
Is Bristol-Myers Squibb Company’s EV/Sales ratio high or low?
Bristol-Myers Squibb Company's EV/Sales ratio of 3.12x is 10% below its 5-year average of 3.47x, near the low end of its 5-year range (2.62x–4.46x).
As of Thursday, June 11, 2026. 4.48% above its 12-month average of 2.99x.
BMY EV/Sales Ratio Chart
BMY Average EV/Sales Ratio Chart
BMY Current vs Average EV/Sales Ratio Chart
BMY EV/Sales Ratio Metrics
EV/SALES RATIO
3.12x
EV/SALES RATIO AVG TTM
2.99x
EV/SALES RATIO AVG 3Y
3.12x
EV/SALES RATIO AVG 5Y
3.47x
EV/SALES RATIO AVG 10Y
4.06x
EV/SALES RATIO AVG 15Y
4.34x
EV/SALES RATIO AVG 20Y
3.91x
CURRENT VS TTM AVG
+4.48%
CURRENT VS 3Y AVG
+0.00%
CURRENT VS 5Y AVG
-10.22%
CURRENT VS 10Y AVG
-23.10%
CURRENT VS 15Y AVG
-28.16%
CURRENT VS 20Y AVG
-20.13%
BMY Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $116.13B | 3.12x | 2.99x | 3.12x | 3.47x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 8.91x | 9.43x | 10.00x | 9.07x |
| Danaher Corporation (DHR) | $126.39B | 5.79x | 6.63x | 7.16x | 7.00x |
| CVS Health Corporation (CVS) | $126.70B | 0.48x | 0.44x | 0.43x | 0.51x |
| Medtronic plc (MDT) | $102.72B | 3.44x | 4.21x | 4.19x | 4.55x |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 13.82x | 18.43x | 19.52x | 18.69x |
| Elevance Health Inc. (ELV) | $86.47B | 0.56x | 0.51x | 0.67x | 0.76x |
| Pfizer Inc. (PFE) | $149.61B | 3.37x | 3.30x | 3.43x | 3.63x |
| Cigna Corporation (CI) | $77.92B | 0.37x | 0.38x | 0.50x | 0.55x |
| Abbott Laboratories (ABT) | $155.75B | 4.07x | 4.94x | 5.00x | 4.98x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Bristol-Myers Squibb Company EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The EV/Sales ratio for BMY stock is 3.12x.
- Is Bristol-Myers Squibb Company's EV/Sales ratio high or low?
- Bristol-Myers Squibb Company's EV/Sales ratio of 3.12x is 10% below its 5-year average of 3.47x, near the low end of its 5-year range (2.62x–4.46x).
- What is the TTM average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The TTM average EV/Sales ratio for BMY stock is 2.99x.
- What is the 3Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The 3Y average EV/Sales ratio for BMY stock is 3.12x.
- What is the 5Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The 5Y average EV/Sales ratio for BMY stock is 3.47x.
- What is the 10Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The 10Y average EV/Sales ratio for BMY stock is 4.06x.
- What is the 15Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The 15Y average EV/Sales ratio for BMY stock is 4.34x.
- What is the 20Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
- The 20Y average EV/Sales ratio for BMY stock is 3.91x.
Bristol-Myers Squibb Company EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-11 | 3.12x |
| 2026-06-10 | 3.06x |
| 2026-06-09 | 3.10x |
| 2026-06-08 | 3.06x |
| 2026-06-05 | 3.13x |
| 2026-06-04 | 3.11x |
| 2026-06-03 | 3.03x |
| 2026-06-02 | 3.02x |
| 2026-06-01 | 3.04x |
| 2026-05-29 | 3.13x |
| 2026-05-28 | 3.12x |
| 2026-05-27 | 3.14x |
| 2026-05-26 | 3.17x |
| 2026-05-22 | 3.23x |
| 2026-05-21 | 3.23x |
| 2026-05-20 | 3.19x |
| 2026-05-19 | 3.18x |
| 2026-05-18 | 3.14x |
| 2026-05-15 | 3.12x |
| 2026-05-14 | 3.11x |
| 2026-05-13 | 3.10x |
| 2026-05-12 | 3.10x |
| 2026-05-11 | 3.07x |
| 2026-05-08 | 3.09x |
| 2026-05-07 | 3.09x |
| 2026-05-06 | 3.10x |
| 2026-05-05 | 3.12x |
| 2026-05-04 | 3.14x |
| 2026-05-01 | 3.17x |
| 2026-04-30 | 3.27x |
| 2026-04-29 | 3.21x |
| 2026-04-28 | 3.23x |
| 2026-04-27 | 3.21x |
| 2026-04-24 | 3.25x |
| 2026-04-23 | 3.27x |
| 2026-04-22 | 3.26x |
| 2026-04-21 | 3.28x |
| 2026-04-20 | 3.27x |
| 2026-04-17 | 3.31x |
| 2026-04-16 | 3.26x |
| 2026-04-15 | 3.22x |
| 2026-04-14 | 3.23x |
| 2026-04-13 | 3.23x |
| 2026-04-10 | 3.25x |
| 2026-04-09 | 3.28x |
| 2026-04-08 | 3.27x |
| 2026-04-07 | 3.21x |
| 2026-04-06 | 3.28x |
| 2026-04-02 | 3.29x |
| 2026-04-01 | 3.38x |
| 2026-03-31 | 3.33x |
| 2026-03-30 | 3.30x |
| 2026-03-27 | 3.25x |
| 2026-03-26 | 3.28x |
| 2026-03-25 | 3.26x |
| 2026-03-24 | 3.20x |
| 2026-03-23 | 3.18x |
| 2026-03-20 | 3.20x |
| 2026-03-19 | 3.23x |
| 2026-03-18 | 3.28x |
| 2026-03-17 | 3.29x |
| 2026-03-16 | 3.29x |
| 2026-03-13 | 3.27x |
| 2026-03-12 | 3.26x |
| 2026-03-11 | 3.31x |
| 2026-03-10 | 3.31x |
| 2026-03-09 | 3.33x |
| 2026-03-06 | 3.32x |
| 2026-03-05 | 3.34x |
| 2026-03-04 | 3.41x |
| 2026-03-03 | 3.36x |
| 2026-03-02 | 3.41x |
| 2026-02-27 | 3.41x |
| 2026-02-26 | 3.35x |
| 2026-02-25 | 3.36x |
| 2026-02-24 | 3.38x |
| 2026-02-23 | 3.36x |
| 2026-02-20 | 3.34x |
| 2026-02-19 | 3.32x |
| 2026-02-18 | 3.30x |
| 2026-02-17 | 3.32x |
| 2026-02-13 | 3.34x |
| 2026-02-12 | 3.30x |
| 2026-02-11 | 3.30x |
| 2026-02-10 | 3.32x |
| 2026-02-09 | 3.31x |
| 2026-02-06 | 3.37x |
| 2026-02-05 | 3.26x |
| 2026-02-04 | 3.18x |
| 2026-02-03 | 3.11x |
| 2026-02-02 | 3.11x |
| 2026-01-30 | 3.07x |
| 2026-01-29 | 3.04x |
| 2026-01-28 | 3.05x |
| 2026-01-27 | 3.09x |
| 2026-01-26 | 3.05x |
| 2026-01-23 | 3.05x |
| 2026-01-22 | 3.07x |
| 2026-01-21 | 3.05x |
| 2026-01-20 | 3.04x |
| 2026-01-16 | 3.08x |
| 2026-01-15 | 3.14x |
| 2026-01-14 | 3.15x |
| 2026-01-13 | 3.11x |
| 2026-01-12 | 3.10x |
| 2026-01-09 | 3.11x |
| 2026-01-08 | 3.11x |
| 2026-01-07 | 3.14x |
| 2026-01-06 | 3.04x |
| 2026-01-05 | 2.99x |
| 2026-01-02 | 3.00x |
| 2025-12-31 | 3.02x |
| 2025-12-30 | 3.04x |
| 2025-12-29 | 3.03x |
| 2025-12-26 | 3.05x |
| 2025-12-24 | 3.06x |
| 2025-12-23 | 3.04x |
| 2025-12-22 | 3.05x |
| 2025-12-19 | 3.03x |
| 2025-12-18 | 3.00x |
| 2025-12-17 | 3.01x |
| 2025-12-16 | 3.04x |
| 2025-12-15 | 3.04x |
| 2025-12-12 | 2.96x |
| 2025-12-11 | 2.91x |
| 2025-12-10 | 2.91x |
| 2025-12-09 | 2.88x |
| 2025-12-08 | 2.93x |
| 2025-12-05 | 2.95x |
| 2025-12-04 | 2.94x |
| 2025-12-03 | 2.90x |
| 2025-12-02 | 2.78x |
| 2025-12-01 | 2.82x |
| 2025-11-28 | 2.82x |
| 2025-11-26 | 2.82x |
| 2025-11-25 | 2.82x |
| 2025-11-24 | 2.76x |
| 2025-11-21 | 2.70x |
| 2025-11-20 | 2.68x |
| 2025-11-19 | 2.68x |
| 2025-11-18 | 2.73x |
| 2025-11-17 | 2.72x |
| 2025-11-14 | 2.71x |
| 2025-11-13 | 2.80x |
| 2025-11-12 | 2.82x |
| 2025-11-11 | 2.80x |
| 2025-11-10 | 2.74x |
| 2025-11-07 | 2.72x |
| 2025-11-06 | 2.71x |
| 2025-11-05 | 2.71x |
| 2025-11-04 | 2.67x |
| 2025-11-03 | 2.69x |
| 2025-10-31 | 2.69x |
| 2025-10-30 | 2.67x |
| 2025-10-29 | 2.62x |
| 2025-10-28 | 2.63x |
| 2025-10-27 | 2.66x |
| 2025-10-24 | 2.68x |
| 2025-10-23 | 2.68x |
| 2025-10-22 | 2.70x |
| 2025-10-21 | 2.71x |
| 2025-10-20 | 2.67x |
| 2025-10-17 | 2.67x |
| 2025-10-16 | 2.66x |
| 2025-10-15 | 2.67x |
| 2025-10-14 | 2.67x |
| 2025-10-13 | 2.66x |
| 2025-10-10 | 2.68x |
| 2025-10-09 | 2.71x |
| 2025-10-08 | 2.71x |
| 2025-10-07 | 2.71x |
| 2025-10-06 | 2.73x |
| 2025-10-03 | 2.75x |
| 2025-10-02 | 2.76x |
| 2025-10-01 | 2.83x |
| 2025-09-30 | 2.73x |
| 2025-09-29 | 2.69x |
| 2025-09-26 | 2.69x |
| 2025-09-25 | 2.66x |
| 2025-09-24 | 2.69x |
| 2025-09-23 | 2.72x |
| 2025-09-22 | 2.73x |
| 2025-09-19 | 2.73x |
| 2025-09-18 | 2.75x |
| 2025-09-17 | 2.78x |
| 2025-09-16 | 2.78x |
| 2025-09-15 | 2.78x |
| 2025-09-12 | 2.78x |
| 2025-09-11 | 2.83x |
| 2025-09-10 | 2.82x |
| 2025-09-09 | 2.82x |
| 2025-09-08 | 2.80x |
| 2025-09-05 | 2.82x |
| 2025-09-04 | 2.80x |
| 2025-09-03 | 2.83x |
| 2025-09-02 | 2.83x |
| 2025-08-29 | 2.82x |
| 2025-08-28 | 2.81x |
| 2025-08-27 | 2.84x |
| 2025-08-26 | 2.82x |
| 2025-08-25 | 2.82x |
| 2025-08-22 | 2.85x |
| 2025-08-21 | 2.87x |
| 2025-08-20 | 2.87x |
| 2025-08-19 | 2.87x |
| 2025-08-18 | 2.86x |
| 2025-08-15 | 2.87x |
| 2025-08-14 | 2.85x |
| 2025-08-13 | 2.85x |
| 2025-08-12 | 2.79x |
| 2025-08-11 | 2.77x |
| 2025-08-08 | 2.77x |
| 2025-08-07 | 2.74x |
| 2025-08-06 | 2.72x |
| 2025-08-05 | 2.76x |
| 2025-08-04 | 2.74x |
| 2025-08-01 | 2.69x |
| 2025-07-31 | 2.65x |
| 2025-07-30 | 2.81x |
| 2025-07-29 | 2.85x |
| 2025-07-28 | 2.88x |
| 2025-07-25 | 2.92x |
| 2025-07-24 | 2.94x |
| 2025-07-23 | 2.94x |
| 2025-07-22 | 2.90x |
| 2025-07-21 | 2.84x |
| 2025-07-18 | 2.87x |
| 2025-07-17 | 2.90x |
| 2025-07-16 | 2.86x |
| 2025-07-15 | 2.83x |
| 2025-07-14 | 2.87x |
| 2025-07-11 | 2.85x |
| 2025-07-10 | 2.92x |
| 2025-07-09 | 2.89x |
| 2025-07-08 | 2.86x |
| 2025-07-07 | 2.84x |
| 2025-07-03 | 2.85x |
| 2025-07-02 | 2.88x |
| 2025-07-01 | 2.88x |
| 2025-06-30 | 2.83x |
| 2025-06-27 | 2.83x |
| 2025-06-26 | 2.84x |
| 2025-06-25 | 2.84x |
| 2025-06-24 | 2.86x |
| 2025-06-23 | 2.85x |
| 2025-06-20 | 2.85x |
| 2025-06-18 | 2.85x |
| 2025-06-17 | 2.87x |
| 2025-06-16 | 2.93x |
| 2025-06-13 | 2.97x |
| 2025-06-12 | 3.01x |
| 2025-06-11 | 2.99x |
| 2025-06-10 | 2.98x |
| 2025-06-09 | 2.94x |
| 2025-06-06 | 2.92x |
| 2025-06-05 | 2.89x |
| 2025-06-04 | 2.90x |
| 2025-06-03 | 2.90x |
| 2025-06-02 | 2.93x |
| 2025-05-30 | 2.91x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner